New hope for tough pancreatic cancer? early trial combines GP-2250 with chemo
NCT ID NCT03854110
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 31 times
Summary
This early-phase study tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has not responded to previous treatment. The main goal is to find a safe dose and check for side effects. About 64 adults with this type of cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center at the University of Pennsylvania
Phildelphia, Pennsylvania, 19104, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hoag Family Cancer Institute
Newport Beach, California, 92663, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27292, United States
Conditions
Explore the condition pages connected to this study.